Your Article Summary
See Latest ArticlesAntigenics' QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial of GlaxoSmithKline's Malaria Vaccine
Antigenics, 06/26/09
Antigenics Inc. announced that GlaxoSmithKline has launched a Phase 3 study with the world's most clinically-advanced malaria vaccine, RTS,S, which contains Antigenics' QS-21 Stimulon adjuvant.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09